MD Anderson Research Highlights for February 26, 2025
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Study identifies biomarkers for predicting treatment response in metastatic breast cancer
Standard...
Public Notice of Scheduled Site Visit to MD Anderson by ANCC Magnet Recognition Program Appraisers
Public Notice
MAGNET RECOGNITION PROGRAM® — SITE VISIT
What is Magnet and why is Magnet important?
ANCC Magnet...
MD Anderson researchers develop novel antibody-toxin conjugate
Researchers at The University of Texas MD Anderson Cancer Center have developed a novel antibody-toxin conjugate (ATC) designed to stimulate...
UT MD Anderson and Texas Children’s Hospital Announce Joint Venture to End Childhood Cancer
The University of Texas MD Anderson Cancer Center and Texas Children’s Hospital have announced a transformational collaboration dedicated solely to pediatric cancer care. Approved by the UT System Board of Regents and the Texas Children’s Board of Trustees, this new, first-of-its-kind joint venture will unite the nation’s largest comprehensive pediatric system and a top pediatric cancer program with the nation’s leading comprehensive...
MD Anderson receives nearly $23 million in CPRIT funding for cancer research, faculty recruitment
The University of Texas MD Anderson Cancer Center today was awarded nearly $23 million from the Cancer Prevention and Research Institute of...
Scientists find new biomarker that predicts cancer aggressiveness
Using a new technology and computational method, researchers from Fred Hutch Cancer Center and The University of Texas MD Anderson Cancer...
MD Anderson Research Highlights for February 10, 2025
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
Combination of dual-targeted therapies and chemotherapy shows high response rates in BRAF-mutated metastatic colorectal cancer
ABSTRACT: 16
Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefitted from first-line treatment...
MD Anderson Research Highlights for January 22, 2025
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
ExxonMobil donates $10 million to fund MD Anderson-led Be Well™ Beaumont initiative
In an effort to improve public health and reduce cancer risk in East Texas, leaders in Beaumont are working with The University of Texas...